Table 4.
Comparison of adverse reactions between the two groups
| Adverse reactions | Nimotuzumab group(n=52) | Control group(n=57) | P value | ||
|---|---|---|---|---|---|
| Grade –2(%) | Grade 3–4 (%) |
Grade 1–2(%) | Grade 3–4(%) | ||
| Leukopenia | 35 (67.3) | 1 (1.9) | 40 (70.1) | 3 (5.3) | 0.739 |
| Hemoglobin decreased | 20 (38.5) | 0 (0.0) | 30 (52.6) | 0 (0.0) | 0.138 |
| Thrombocytopenia | 4 (7.7) | 0 (0.0) | 6 (10.5) | 2 (3.5) | 0.515 |
| ALT increased | 9 (17.3) | 0 (0.0) | 16 (28.1) | 0 (0.0) | 0.182 |
| AST increased | 2 (3.8) | 0 (0.0) | 5 (8.8) | 0 (0.0) | 0.511 |
| Urea increased | 2 (3.8) | 0 (0.0) | 2 (3.5) | 0 (0.0) | 0.925 |
| Nausea | 18 (34.6) | 0 (0.0) | 17 (29.8) | 0 (0.0) | 0.593 |
| Vomiting | 7 (13.5) | 0 (0.0) | 11 (19.3) | 0 (0.0) | 0.412 |
| Oral mucositis | 44 (84.6) | 8 (15.4) | 50 (87.7) | 7 (12.3) | 0.638 |
| Radiodermatitis | 51 (98.1) | 1 (1.9) | 56 (98.2) | 1 (1.8) | 1.000 |
| Pharyngeal and esophageal reactions | 49 (94.2) | 3 (5.8) | 56 (98.2) | 1 (1.8) | 0.546 |
| Weight loss | 52 (100.0) | 0 (0.0) | 57 (100.0) | 0 (0.0) | - |
| Hyponatremia | 4 (7.7) | 0 (0.0) | 3 (5.3) | 0 (0.0) | 0.900 |
| Hypokalemia | 17 (32.7) | 2 (3.8) | 12 (21.1) | 2 (3.5) | 1.000 |
| Skin rash | 1(1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Infusion reaction | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
—is unable to calculate statistics